Friday POW!
Pick of the Week!
Key Highlights
Stock at ~$133; 52-week range of $107.75 to $157.29;
Q1 2026: revenue $6.96B, +4.4% YoY, 1.5% beat; adj. EPS $2.03, +6.3% beat; adj. operating income $3.27B, 46.9% margin, 4.7% beat; operating margin 37.2%, up from 33.5% YoY
Q2 2026 (August 4): Generally Accepted Accounting Principles (GAAP) net loss $10.5B driven by acquisition write-downs; underlying revenue growth strong; HIV and oncology both growing; full-year product sales guidance raised to $30.1B
